Skip to main content
Journal of Thoracic Disease logoLink to Journal of Thoracic Disease
. 2016 Jan;8(1):E161. doi: 10.3978/j.issn.2072-1439.2016.01.51

Erratum to clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy

PMCID: PMC4740129  PMID: 26904249

In the article that appeared on Page 1898-1906 (1) of the November 2015 Issue of the Journal of Thoracic Disease, there were needless legends in Figure 2A and 4A: PLR <215, PLR ≥215 and P=0.014 in Figure 2A; Risk 0, 1, 2 and P=0.0002 in Figure 4A. The legends mentioned above should be deleted.

Figure 2.

Figure 2

(A) Kaplan-Meier curve for overall survival of 65 patients in the training cohort. The median survival time was 23.7 months and the overall 2- and 5-year survival was 48.7% and 21.7%, respectively.

Figure 4.

Figure 4

(A) Kaplan-Meier curve for overall survival of 32 patients in the validation cohort. The median survival time was 37.4 months and the overall 2- and 5-year survival was 74.6% and 26.9%, respectively.

Therefore, the correct figures are as follows:

The publisher regrets these errors.

References

  • 1.Tagawa T, Anraku M, Morodomi Y, et al. Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy. J Thorac Dis 2015;7:1898-906. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Thoracic Disease are provided here courtesy of AME Publications

RESOURCES